529
Participants
Start Date
April 23, 2009
Primary Completion Date
June 1, 2012
Study Completion Date
February 12, 2014
ABI-007
Patients who receive ABI-007 will be dosed intravenously over approximately 30 minutes without steroid pre-medication and without G-CSF prophylaxis (unless modified as described below). ABI-007 150 mg/m2 will be administered on Days 1, 8, and 15 every 4 weeks.
Dacarbazine
Patients who receive dacarbazine will be dosed intravenously at 1000 mg/m2 on Day 1 with steroid and antiemetic pre-medication. Treatment will be repeated every 21 days.
Medisch Centrum Alkmaar, Alkmaar
Royal North Shore Hospital, Sydney
Sydney West Cancer Trials Centre/Westmead Hospital, Westmead
Port Macquarie Base Hospital, Port Macquarie
Alfred Hospital, Melbourne
Royal Adelaide Hospital, Department of Medical Oncology, Adelaide
Royal Perth Hospital, Perth
Royal Hobart Hospital, Hobart
Charite Universitaetsmedizin Berlin, Berlin
IST-Istituto Nazionale per la Ricera sul Cancro, Genova
St. Luke's Hospital & Health Network, Bethlehem
Thomas Jefferson University, Philadelphia
Istituto Europeo di Oncologia, Milan
Universitaetsklinkum Schegwig-Holstein, Keil
Piedmont Hematology, Winston-Salem
Medizinische Hochschuke Hannover, Hanover
Baptist Cancer Institute, Jacksonville
Hopital Saint Andre' CHU de Bordeaux, Bordeaux
University of Miami Hospital and Clincs/SCCC, Miami
Lakeland Regional Cancer Center, Lakeland
Centre Regional Val d' Aurelle Paul Lamarque, Montpellier
IOV-Instituto Oncologico IRCCS, Padua
University of Alabama at Birmingham, Birmingham
Centre Hospitaller Universitaire de Grenoble, Grenoble
OH State University Arthur G. James Cancer Hospital, Columbus
St. Josef-Hospital, Bochum
Indiana University, Indianapolis
Istituto Scientifico Romagnolo per lo Studio e la Cura dei T, Meldola
Wayne State University, Detroit
IA Blood and Cancer Care, PLC, Cedar Rapids
Azienda Ospedaliera Universitaria Sense, Siena
University of Minnesota, Minneapolis
Ospedale S. Chiara, Pisa
Waren Billhartz Cancer Center, Maryville
Saint Louis University, St Louis
St. John's Medical Research, Springfield
Genesis Cancer Ctr - Hot Springs, Hot Springs
Universitaetsklinkum Tuebingen, Tübingen
University of Arkansa for Medical Sciences, Little Rock
Integris Cancer Institute of OK, Oklahoma City
Hopital Bichat, Paris
Hope Oncology, Richardson
Mary Crowley Research Center, Dallas
Univ of TX MD Anderson Cancer Ctr, Houston
Univ of TX Med School at Houston, Houston
Covenant Health System DBA Joe Arrington Cancer Research and Treatment Center, Lubbock
University of Colorado Cancer Center, Aurora
Ist. Naz. per lo studio e la cura dei tumori G. Pascale, Napoli
Utah Cancer Specialist, Salt Lake City
AZ Cancer Ctr, Scottsdale
Arizona Cancer Center, Tucson
Nevada Cancer Institute, Las Vegas
University of Southern California/Norris Cancer Center, Los Angeles
University of CA Los Angeles, Los Angeles
Tower Cancer Research Foundation, Beverly Hills
San Diego Pacific Oncology and Hematology Associates, Encinitas
Loma Linda University Cancer Center, Loma Linda
St. Mary's Medical Center, San Francisco
Institut Gustave Roussy (IGR) Centre de Lutte Contre le Canc, Villejuif
Universitaetsklinkum Wuerzburg PS, Würzburg
Univ. of Washington Medical Center/Seattle Cancer Care Alliance, Seattle
Evergreen Hematology & Oncology, Spokane
Beth Israel Deaconess Medical Center, Boston
Atlantic Melanoma Center, Morristown
Sir Charles Gairdner Hospital, Nedlands Perth
CHRU Hopital Claude Huriez, Lile Cedax
Hopital Dypuytren-CHU de Limoges, Limoges
Centre Leon Berad, Lyon
Hopital Sainte Marguerite, Marseille
CHU Hopital Saint Eloi, Montepellier Cedex 5
Groupe hospitalier Cochin-St. Vincent de Paul, Paris
Hopital Saint-Louis, Paris
Universitaetsklinkum Heidelberg, Heidelberg
Universitaetsklinkum Heidelberg, Heidelber
Universitaetsklinkum Hamburg-Eppendorf, Hamburg
Univeritaetsklinkum Goettingen, Gottington
Universitaetklinkum Koeln, Cologne
Universitaetsklinkum Essen, Essen
Universitaetsklinkum Dresden, Dresden
Universitaesklinkum Leipzig, Leipzig
Universitaetsklinkum Mainz, Mainz
"Istituto Tumori Giovanni Paolo II", Bari
Istituto Nazionale Tumori, Milan
"Erasmus MC ae Daniel den Hoed", Rotterdam
H CLINIC I Provincial, Barcelona
H Clinico San Carlos, Madrid
Tom Baker Cancer Centre, Calgary
Cross Cancer Institute, Edmonton
BCCA Centre for the Southern Interior, Kelowna
BCCA, Centre for the Southern Interior, Kelowna
BC Cancer Agency-Fraser Valley Ctr., Surrey
BC Cancer Agency-Vancouver, Vancouver
BC Cancer Agency-Vancouver Island Ctr., Victoria
London Regional Cancer Program, London
Credit Valley Hospital, Missiauga
The Ottawa Hospital Regional Cancer Centre, Ottawa
Sunnybrook Health Sciences Centre, Toronto
McGill University Dept. of Oncology Clinical Research Program, Montreal
Hopital de 1 Archet 2, Nice
UniversitawtsklinKum Jena, Jena
Rijnstate ziekenhuis Arnhem, Amhem
H Clinic i Provincial, Barcelona
Corporacion Sanitaria Parc Tauli, Sabadell
Broomfield Hospital, Chelmsford
Velindre Hospital, Cardiff
St. George's Hospital, London
Nottingham University Hospitals NHS Trust, Nottingham
Singleton Hospital, Sothwest Wales Inst., Swansea
Univ Hospital of North Staffordshire, Stroke on Kent
Weston Park Hospital, Sheffield
Newcross Hospital, Wolverhampton
Royal Marsden Hospital London, London
Lead Sponsor
University of Arizona
OTHER
Celgene
INDUSTRY